HRP20010191A2 - Treatment of depression - Google Patents

Treatment of depression Download PDF

Info

Publication number
HRP20010191A2
HRP20010191A2 HR20010191A HRP20010191A HRP20010191A2 HR P20010191 A2 HRP20010191 A2 HR P20010191A2 HR 20010191 A HR20010191 A HR 20010191A HR P20010191 A HRP20010191 A HR P20010191A HR P20010191 A2 HRP20010191 A2 HR P20010191A2
Authority
HR
Croatia
Prior art keywords
treatment
day
depression
compound
use according
Prior art date
Application number
HR20010191A
Other languages
English (en)
Croatian (hr)
Inventor
Connie Sanchez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HRP20010191A2 publication Critical patent/HRP20010191A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20010191A 1998-09-15 1999-09-14 Treatment of depression HRP20010191A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801163 1998-09-15
PCT/DK1999/000482 WO2000015225A1 (en) 1998-09-15 1999-09-14 Treatment of depression

Publications (1)

Publication Number Publication Date
HRP20010191A2 true HRP20010191A2 (en) 2002-04-30

Family

ID=8101704

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010191A HRP20010191A2 (en) 1998-09-15 1999-09-14 Treatment of depression

Country Status (25)

Country Link
US (1) US6358966B2 (pt)
EP (1) EP1121122A1 (pt)
JP (1) JP2002524515A (pt)
KR (1) KR20010075120A (pt)
CN (1) CN1317969A (pt)
AR (1) AR021805A1 (pt)
AU (1) AU5617499A (pt)
BG (1) BG105378A (pt)
BR (1) BR9913964A (pt)
CA (1) CA2343761A1 (pt)
CZ (1) CZ2001946A3 (pt)
EA (1) EA200100355A1 (pt)
HK (1) HK1040922A1 (pt)
HR (1) HRP20010191A2 (pt)
HU (1) HUP0103568A3 (pt)
ID (1) ID29414A (pt)
IL (1) IL141880A0 (pt)
IS (1) IS5873A (pt)
NO (1) NO20011268L (pt)
PL (1) PL346528A1 (pt)
SK (1) SK3502001A3 (pt)
TR (1) TR200100767T2 (pt)
WO (1) WO2000015225A1 (pt)
YU (1) YU18701A (pt)
ZA (1) ZA200101910B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
KR20010042502A (ko) * 1998-04-07 2001-05-25 피터슨 존 메이달 공황 발작의 치료

Also Published As

Publication number Publication date
US20010020027A1 (en) 2001-09-06
TR200100767T2 (tr) 2001-07-23
YU18701A (sh) 2003-07-07
NO20011268D0 (no) 2001-03-13
HUP0103568A3 (en) 2003-05-28
AR021805A1 (es) 2002-08-07
US6358966B2 (en) 2002-03-19
KR20010075120A (ko) 2001-08-09
CA2343761A1 (en) 2000-03-23
IL141880A0 (en) 2002-03-10
HK1040922A1 (zh) 2002-06-28
CZ2001946A3 (cs) 2001-09-12
ZA200101910B (en) 2001-09-11
BR9913964A (pt) 2001-07-03
CN1317969A (zh) 2001-10-17
EP1121122A1 (en) 2001-08-08
IS5873A (is) 2001-02-28
SK3502001A3 (en) 2001-12-03
NO20011268L (no) 2001-05-15
JP2002524515A (ja) 2002-08-06
AU5617499A (en) 2000-04-03
ID29414A (id) 2001-08-30
EA200100355A1 (ru) 2001-08-27
BG105378A (bg) 2001-12-29
WO2000015225A1 (en) 2000-03-23
HUP0103568A2 (hu) 2002-01-28
PL346528A1 (en) 2002-02-11

Similar Documents

Publication Publication Date Title
McNaught et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
Prendergast et al. Hippocampal CA1 region neurodegeneration produced by ethanol withdrawal requires activation of intrinsic polysynaptic hippocampal pathways and function of N-methyl-D-aspartate receptors
DE69832688T2 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
Anand et al. The animal models of dementia and Alzheimer’s disease for pre-clinical testing and clinical translation
JPH04226917A (ja) 神経退化過程における予防及び治療用医薬
RS58900B1 (sr) Nukleofilni katalizator za vezivanje oksima
Andreassen et al. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats
Jonnala et al. Relative levels of cytoprotection produced by analogs of choline and the role of α7‐nicotinic acetylcholine receptors
DE69933885T2 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
Carles et al. The selective butyrylcholinesterase inhibitor UW‐MD‐95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease
Lu et al. Kai Xin San aqueous extract improves Aβ1-40-induced cognitive deficits on adaptive behavior learning by enhancing memory-related molecules expression in the hippocampus
HRP20010191A2 (en) Treatment of depression
Mulder et al. Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum
DE60120925T2 (de) Isatinderivate mit neurotropen aktivität
CN106361736B (zh) 一种胍基化合物的应用
KR102428383B1 (ko) 중추신경계 및 혈관계에 대한 활성을 가진 벤조디아제핀 생성물
CN100354274C (zh) 神经变性疾病的预防和治疗药物
Hetman et al. Increased expression of cathepsin D in retrosplenial cortex of MK-801-treated rats
MXPA01002661A (en) Treatment of depression
US6262061B1 (en) Treatment of panic attacks
Yaari et al. Cognitive enhancers and treatments for Alzheimer's disease
MXPA00009506A (en) Treatment of panic attacks
JPH1160482A (ja) 性機能改善剤
JP2011020957A (ja) アルツハイマー病治療薬
ECHEVERRIA et al. Cotinine: a potential new therapeutic agent against Alzheimer’s

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20020914

Year of fee payment: 4

OBST Application withdrawn